MARKET

ATOS

ATOS

Atossa Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.540
+0.130
+9.22%
After Hours: 1.540 0 0.00% 19:57 01/20 EST
OPEN
1.420
PREV CLOSE
1.410
HIGH
1.550
LOW
1.280
VOLUME
21.48M
TURNOVER
--
52 WEEK HIGH
5.08
52 WEEK LOW
0.7550
MARKET CAP
109.95M
P/E (TTM)
-1.1176
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Wall Street Analysts Are Bullish on Top Healthcare Picks
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atossa Therapeutics (ATOS) and Masimo (MASI) with bullish
SmarterAnalyst · 15h ago
COVID-19 Origin and Spread Linked to PLA Hospital and Wuhan Metro System Line 2 by Physician-Scientist Dr. Steven Quay
, /PRNewswire/ -- Dr. Steven Quay, M.D., PhD., head of two COVID-19 therapeutic programs at  Atossa Therapeutics, Inc. (NASDAQ: ATOS ), recently shared his latest research and findings regarding the origins of COVID-19 and the manner in which it spread so...
PR Newswire - PRF · 01/08 11:02
COVID-19 Origin and Spread Linked to PLA Hospital and Wuhan Metro System Line 2 by Physician-Scientist Dr. Steven Quay
PR Newswire · 01/08 11:02
CLSK, ISR, SYN and BBI among midday movers
Gainers: Isoray (ISR) +187%.The9 (NCTY) +48%.9 Meters Biopharma (NMTR) +40%.AIkido Pharma (AIKI) +40%.Guardion Health Sciences (GHSI) +38%.TAT Technologies (TATT) +35%.Orchard Therapeutics (ORTX) +35%.Change Healthcare (CHNG) +31%.CleanSpark (CLSK) +30%.CBAK Energy Technology (CBAT) +28%.Losers: IMARA (IMRA) -35%.Second Sight Medical Products (EYES) -23%.Mexco
Seekingalpha · 01/06 17:47
Isoray, Guardion Health Sciences leads healthcare gainers; IMARA, Synthetic Biologics among major losers
Gainers: Isoray (ISR) +181%, Guardion Health Sciences (GHSI) +57%, AIkido Pharma AIKI +57%, Orchard Therapeutics ORTX +41%, Change Healthcare CHNG +31%.Losers: IMARA IMRA -35%, Synthetic Biologics (SYN) -25%, Second Sight Medical Products (EYES) -22%, Atossa Therapeutics ATOS -21%, Brickell Biotech (BBI) -10%.
Seekingalpha · 01/06 16:01
Atossa Therapeutics prices ~$25M direct offering, stock -23% PM
Atossa Therapeutics (ATOS) announces $25.2M direct offering to institutional investors in a deal priced at-the-market.The combined purchase price for a common share and .75 warrants to purchase one share of common
Seekingalpha · 01/06 14:28
Atossa Therapeutics Announces Pricing of $25.2 Million Registered Direct Offering Priced At-The-Market
Atossa Therapeutics, Inc. (Nasdaq: ATOS) (the "Company" or "Atossa"), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID...
GlobeNewswire · 01/06 14:15
Atossa Therapeutics Announces Pricing of $25.2 Million Registered Direct Offering Priced At-The-Market
GlobeNewswire · 01/06 14:15
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATOS. Analyze the recent business situations of Atossa Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATOS stock price target is 6.25 with a high estimate of 7.50 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 30
Institutional Holdings: 731.19K
% Owned: 1.02%
Shares Outstanding: 71.40M
TypeInstitutionsShares
Increased
4
221.92K
New
13
221.99K
Decreased
3
20.95K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.31%
Pharmaceuticals & Medical Research
-0.03%
Key Executives
Chairman/Chief Executive Officer/President/Director
Steven Quay
Chief Financial Officer/General Counsel/Secretary
Kyle Guse
Director
Shu-Chih Chen
Independent Director
Stephen Galli
Independent Director
H. Lawrence Remmel
Independent Director
Richard Steinhart
Independent Director
Gregory Weaver
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ATOS
Atossa Therapeutics Inc., formerly Atossa Genetics Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics and delivery methods for breast cancer and other breast conditions. Its pipeline includes two programs: endoxifen and intraductal microcatheter technology. It is developing Topical Endoxifen formulation for transdermal delivery. It is developing Topical Endoxifen to address two populations: to reduce mammographic breast density (MBD) and to prevent/reduce gynecomastia in prostate cancer patients starting androgen deprivation therapy. It is also developing oral presentation of endoxifen. It is developing its microcatheter technology to deliver therapeutics through the nipple directly to the site of early breast cancer. It is also developing our proprietary intraductal microcatheter technology for Chimeric Antigen Receptor Therapy (CAR-T).
More

Webull offers kinds of Atossa Therapeutics Inc stock information, including NASDAQ:ATOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATOS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATOS stock methods without spending real money on the virtual paper trading platform.